The San Diego Business Journal featured Synthorx in an article about synthetic biology. The reporter describes the field as a blend of engineering and biotechnology that allows scientists to build new and re-configure existing biological systems.
Synthorx has developed a way to introduce two new DNA bases into a living system (lab strains of E. coli bacteria). This technique greatly expands the genetic alphabet to encode for new proteins. As the article explains, the possible applications for this technology are numerous.
Court Turner, Synthorx CEO, is interviewed in the article. He explains that Synthorx is working toward making novel protein therapeutics by using the company’s expanded genetic alphabet technology platform.